Tyrosol May Prevent Obesity by Inhibiting Adipogenesis in 3T3-L1 Preadipocytes

Pacifici, Francesca; Farias, Carolina Lane Alves; Rea, Silvia; Capuani, Barbara; Feraco, Alessandra; Coppola, Andrea; Mammi, Caterina; Pastore, Donatella; Abete, Pasquale; Rovella, Valentina; Salimei, Chiara; Lombardo, Mauro; Caprio, Massimiliano; Bellia, Alfonso; Sbraccia, Paolo; Di Daniele, Nicola; Lauro, Davide; Della-Morte, David

doi:https://doi.org/10.1155/2020/4794780

Oxidative Medicine and Cellular Longevity

On this page

Abstract Introduction Materials and Methods Results Discussion Conclusions Data Availability Conflicts of Interest Acknowledgments References Copyright Related Articles

Special Issue

How Dietary Natural Molecules, Redox Biology, Bioenergetics and Immune Function Impact Health and Disease

View this Special Issue

Research Article | Open Access

Volume 2020 | Article ID 4794780 | https://doi.org/10.1155/2020/4794780

Tyrosol May Prevent Obesity by Inhibiting Adipogenesis in 3T3-L1 Preadipocytes

Francesca Pacifici,¹Carolina Lane Alves Farias,^2,3Silvia Rea,¹Barbara Capuani,¹Alessandra Feraco,⁴Andrea Coppola,¹Caterina Mammi,⁴Donatella Pastore,¹Pasquale Abete,⁵Valentina Rovella,⁶Chiara Salimei,⁷and Mauro Lombardo⁸ et al.

Academic Editor: Marcos R. de Oliveira

Received24 Jul 2020

Revised08 Nov 2020

Accepted19 Nov 2020

Published10 Dec 2020

Abstract

Tyrosol (TR), a major polyphenol found in extra virgin olive oil (EVOO), exerts several antioxidant effects. However, only scarce evidences are present regarding its activity on adipocytes and obesity. This study evaluated the role of TR in adipogenesis. Murine 3T3-L1 preadipocytes were incubated with TR (300 and 500 μM), and TR administration inhibited adipogenesis by downregulation of several adipogenic factors (leptin and aP2) and transcription factors (C/EBPα, PPARγ, SREBP1c, and Glut4) and by modulation of the histone deacetylase sirtuin 1. After complete differentiation, adipocytes treated with 300 and 500 μM TR showed a reduction of 20% and 30% in lipid droplets, respectively. Intracellular triglycerides were significantly reduced after TR treatment (). Mature adipocytes treated with TR at 300 and 500 μM showed a marked decrease in the inflammatory state and oxidative stress as shown by the modulation of specific biomarkers (TNF, IL6, ROS, and SOD2). TR treatment also acted on the early stage of differentiation by reducing cell proliferation (~40%) and inducing cell cycle arrest during Mitotic Expansion Clonal (first 48 h of differentiation), as shown by the increase in both S1 phase and p21 protein expression. We also showed that TR induced lipolysis by activating the AMPK-ATGL-HSL pathway. In conclusion, we provided evidence that TR reduces 3T3-L1 differentiation through downregulation of adipogenic proteins, inflammation, and oxidative stress. Moreover, TR may trigger adipose tissue browning throughout the induction of the AMPK-ATGL-UCP1 pathway and, subsequently, may have promise as a potential therapeutic agent for the treatment and prevention of obesity.

1. Introduction

Obesity is a pandemic public health problem, especially in developing countries, where the prevalence is increasing exponentially in the last decades [1]. Obesity is considered the leading cause of risk for cardiovascular disease (CVD) and metabolic diseases [2]. It is a complex disorder with multifactorial etiology, characterized by an imbalance between energy intake and energy expenditure, which, in turn, induces a pathological growth of adipose tissue [3, 4]. Adipose tissue is not a passive reservoir for energy storage. It takes, in fact, an important role in the regulation of energetic and endocrine homeostasis, by controlling the release of anti- and proinflammatory adipokines, like leptin [5]. Alterations in adipocyte biology, typical of obesity state, lead to systemic inflammation, increase in chronic oxidative stress, and obesity-related diseases [3]. Thus, strategies able to reduce the pathological inflammatory state and oxidative stress mediated by adipocyte dysfunction may be helpful in counteracting the epidemic burden of obesity.

Among the main strategies proposed to prevent obesity in adults, including increase in physical activity [6] and caloric restriction [7], the increase in consumption of food enriched with anti-inflammatory and antioxidant compounds, such as polyphenols [8], recently raised attention. Polyphenols, such as resveratrol and quercetin, which are secondary metabolites of plants, have been reported to exert antiobesity effects by acting at different levels on adipocyte maturation [9]. In particular, they regulate preadipocyte proliferation, block adipogenesis, and induce apoptosis [10]. Polyphenols are present in the Mediterranean diet, which is a plant-based diet that became a cornerstone for the prevention of chronic diseases [11]. The Mediterranean diet, compared to other dietary regimens, exerts more beneficial health effects just for the presence of a high intake of unique polyphenols contained in the extra virgin olive oil (EVOO), among others [11, 12]. EVOO contains more than 30 polyphenolic compounds; among those, in particular, hydroxytyrosol (HT) and Tyrosol (TR) are the most absorbed and, thus, bioavailable in humans [13, 14]. TR is absorbed after ingestion in a dose-dependent manner via passive diffusion, and in humans, the absorption is as high as 55–66% since it becomes conjugated to glucuronic acid and excreted in urine as glucuronides. Therefore, a high concentration of TR is suggested to exert its effect [15]. A recent study reported that HT and oleuropein (another EVOO polyphenolic compound) prevent adipogenesis and reduce preadipocyte proliferation [16], suggesting that these phytochemicals might prevent obesity. Another interesting study already demonstrated that high doses of TR (0.1–1 mg/mL) are able to reduce differentiation of preadipocytes [17]. Nevertheless, to the best of our knowledge, at the moment, no data regarding possible mechanisms involved in the beneficial role of TR in adipogenesis and therefore obesity are present. In the present study, we sought to evaluate the direct effects of TR on adipogenesis by using a murine 3T3-L1 preadipocyte cell line.

2. Materials and Methods

2.1. Cell Culture and Adipocyte Differentiation

Mouse 3T3-L1 cells were gently provided by Dr. Massimiliano Caprio (San Raffaele Open University, Rome, Italy) and cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Thermo Fisher Scientific, Waltham, Massachusetts, USA), containing 10% fetal calf serum (ATCC, Manassas, Virginia, USA) and 1% penicillin/streptomycin (Thermo Fisher Scientific) and maintained at 37°C in a humidified, 5% CO₂ atmosphere. Cells were differentiated 2 days after reaching confluence, then were stimulated with DMEM (4.5 g/L glucose) containing 10% fetal bovine serum (FBS) (Corning, New York, USA), 1 μg/mL insulin, 0.5 mM isobutylmethylxanthine (IBMX), 1 μM dexamethasone, 300 or 500 μM of Tyrosol (TR) (; Cayman Chemicals, Ann Arbor, Michigan, USA), or DMSO (for control cells) (Sigma Aldrich, Saint Louis, Missouri, USA) for 2 days. On day 2, the differentiation medium was replaced with DMEM (4.5 g/L glucose) containing 10% FBS, 1 μg/mL insulin, and 300 or 500 μM of TR or DMSO (for control cells) until day 4. Then, the medium was replaced with DMEM (4.5 g/L glucose) containing 10% FBS and 300 or 500 μM of TR or DMSO (for control cells) changed every 2 days until day 10 [18].

2.2. Oil Red O Staining

The Oil Red O staining protocol was modified by Rizzatti et al. [19]. Differentiated cells were washed with phosphate buffer saline (PBS, pH 7.4, Sigma Aldrich) and fixed with 4% formalin (Sigma Aldrich) for 20 minutes (min) at room temperature. Then, cells were washed with double distilled water and then incubated with 60% isopropanol for 5 min at room temperature (Sigma Aldrich). Subsequently, cells were stained with Oil Red O solution (0.5 g/L, Sigma Aldrich) for 30 minutes (min) at room temperature and then washed exhaustively with double distilled water. Pictures were taken using an optical microscope. Moreover, Oil Red O dye retained in the cell was dissolved by pure isopropanol and quantified at 490 nm by using a microplate reader.

2.3. Triglyceride Quantification

Triglycerides (TG) were quantified by using the Triglyceride Colorimetric Assay Determination Kit (Cayman Chemicals), according to the manufacturer’s protocol. Once TG content was measured, it was then normalized for mg of proteins and reported as mg of TG per mg of cellular protein, according to Roh et al. [20].

2.4. Tyrosol Toxicity Assay

Tyrosol toxicity was evaluated during the differentiation protocol at different time points: day 2, day 4, and day 8, by using the (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Sigma Aldrich) according to the manufacturer’s protocol.

2.5. Cell Proliferation Assay

Cell proliferation was analyzed by 0.5% Trypan blue staining exclusion (Sigma Aldrich). Viable cells were calculated as the percentage ratio of the number of unstained cells relative to the total cells counted.

2.6. Gene Expression Analysis by Real-Time PCR

Gene expression analysis was performed as previously reported [21]. Briefly, total RNA was isolated using the TRIzol reagent (Thermo Scientific). Two and one-half micrograms of total RNA was reverse transcribed into cDNA using a High-Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA). Inventories under patent primers for leptin, aP2, TNFα, IL6, UCP1, and actin were purchased from Applied Biosystems. The relative expression was calculated using the comparative ∆∆CT method, and the values were expressed as 2^-∆∆CT.

2.7. Western Blot Analysis

Western blot analysis was performed as previously described by Pacifici et al. [21]. Briefly, cells were lysed at 4°C in HNTG lysis buffer (1% TritonX-100, 50 mM HEPES, 10% glycerol, 150 mM NaCl, and 1% sodium deoxycholate) supplemented with Phosphatase Inhibitor Cocktail 2 and 3 (Sigma Aldrich) and protease inhibitor cocktail (Sigma Aldrich). Then, proteins were separated on 4-12% SDS polyacrylamide gels (Bio-Rad Laboratories, MI, Italy) and then transferred electrophoretically to nitrocellulose membranes, using the Trans-Blot Turbo System (Bio-Rad Laboratories). The immunoreactive bands were visualized using the Enhanced Chemiluminescence (ECL) kit (GE Healthcare, Little Chalfont, UK) according to the recommendations of the manufacturer. The membrane was exposed to the ChemiDoc System (Bio-Rad Laboratories) and analyzed using Image Lab Software (Bio-Rad Laboratories). Antibodies specific for PPARγ, CEBPα, SREBP1c (Novus Biological, Centennial, Colorado, USA), Glut-4, SOD2, AMPK-α, phospho-AMPK-α (Thr172), HSL, phospho-HSL (Ser565), ATGL (Cell Signaling Technology, Danvers, Massachusetts, USA), Sirt1 and phospho-ATGL (Ser406) (Abcam Cambridge, UK), p21, cyclin D3, and vinculin (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used.

2.8. ROS Evaluation

Reactive Oxygen Species (ROS) levels were measured by using the MitoSOX Red dye (Thermo Fisher Scientific) following the manufacturer’s protocol. The quantification of dye fluorescence was assessed by cytofluorimetric analysis.

2.9. Cell Cycle Analysis

Cell cycle analysis was performed in fully differentiated 3T3-L1 treated both with TR 300 and 500 μM, modifying the protocol by Drira et al. [16]. Cells were trypsinized, centrifuged, and fixed with ethanol 70% for 30 min. Then, cells were centrifuged, stained with Propidium Iodide solution, and incubated at +4°C for 45 min. Subsequently, cytofluorimetric analysis was performed.

2.10. Statistical Analysis

Data were analyzed using Prism 5 (GraphPad, La Jolla, CA) and expressed as the . Statistical significance was determined with Student’s -test when two experimental groups are present. For more than two groups, statistical evaluation of the data was performed using the ANOVA test, followed by Bonferroni’s post hoc test with considered significant.

3. Results

3.1. TR Inhibits 3T3-L1 Differentiation

To investigate whether TR might inhibit adipocyte maturation, differentiation of 3T3-L1 was induced and the intracellular storage of lipids was assessed by performing Oil Red O staining on day 10. Treatment with TR significantly reduced lipid accumulation at both 300 and 500 μM, in a dose-dependent manner, compared with control cells (Figure 1(a)). This result was confirmed by measurement of Oil Red O absorbance at 490 nm. Lipid accumulation in 3T3-L1 was significantly reduced by 20% and 30% following 300 and 500 μM of TR treatment, respectively, compared to the control ( and , respectively). To further confirm the reduction in intracellular lipid accumulation, and then adipocyte maturation, the cellular content of triglycerides (TG) was measured. A significant decrease in intracellular TG amount was evident at 300 μM than 500 μM of TR (), compared to differentiated control cells (Figure 1(b)). Moreover, inhibition in adipocyte differentiation was also validated by measuring leptin and aP2 levels, specific markers of adipose tissue differentiation status and inflammatory state [22, 23]. TR at 500 μM significantly decreased both levels of leptin and aP2, confirming the effect on TR as an antiadipogenic compound (Figures 1(c) and 1(d)). Moreover, we also tested whether TR reduces adipogenesis by blunting cell viability during the differentiation protocol. As showed in Figure 1(e), TR did not reduce cell viability, further confirming its direct effect on adipogenesis. Taken together, all these results highlight the relevant role of TR in reducing adipocyte differentiation that may greatly contribute to a lower adipose cell mass accumulation.

(a)

(b)

(c)

(d)

(e)

Figure 1

Oil Red O staining and relative triglyceride content in 3T3-L1 adipocytes. Cells were seeded at a density of cells/well in a 24-well plate. Differentiation was induced with or without TR up to day 10. Cells were, then, stained with Oil Red O, and the lipid droplet storage was visualized in optical microscopy and quantified by measuring absorbance (a). Relative triglyceride (TG) content was also evaluated and normalized to mg of protein (b). Leptin (c) and aP2 (d) levels were also evaluated by qRT-PCR. Cell viability was assessed by performing an MTT assay (e). Results are expressed as the . , , and . Graphs illustrate three different experiments conducted separately.

3.2. TR Blunts Adipogenesis by Controlling CEBP/α and Sirt1/PPARγ Pathways

In order to explore the molecular mechanisms beyond the antiadipogenic effect of TR, we evaluated protein expression levels of CEBP/α, PPARγ, Glut4, and SREBP1c, as key regulatory factors of adipogenesis [24–26]. As expected, after 10 days, 500 μM of TR treatment during cellular differentiation significantly reduced expression of both CEBP/α () and PPARγ proteins (), compared to control cells (Figures 2(a) and 2(b)). Similarly, a decreased expression of Glut4 and SREBP1c was observed in cells treated with 500 μM () of TR at the latest stage of differentiation (Figures 2(c) and 2(d)). These findings suggest that TR blunts adipogenesis by impairing CEBP/α and PPARγ pathways.

(a)

(b)

(c)

(d)

(e)

Sirt1 is a major regulator of lipid metabolism and adipogenesis. In particular, Sirt1 blunts adipogenesis by impairing PPARγ expression [27]. In agreement with these evidences, a significant enhancement in Sirt1 expression was present following TR administration at 300 than 500 μM (), compared to untreated cells, suggesting that the antiadipogenic effect of TR may be mediated by the Sirt1/PPARγ pathway.

3.3. TR Exerts Both Anti-inflammatory and Antioxidant Effects

Adipogenesis is characterized by an enhanced proinflammatory state [28]. In agreement with reported previous results on reduced adipogenesis mediated by TR administration, we also evaluated whether TR reduces the proinflammatory state, typical of adipocyte differentiation. In particular, we examined TNFα mRNA levels in fully differentiated adipocytes treated with TR. TNFα levels were significantly reduced by TR at both 300 and 500 μM ( and , respectively) compared to control cells (Figure 3(a)).

(a)

(b)

(c)

Figure 3

Anti-inflammatory and antioxidant effect of TR. Cells were seeded at a density of cells/well in a 6-well plate. Differentiation was induced with or without TR up to day 10. mRNA levels of TNFα (a) were evaluated by qRT-PCR. (b) ROS levels were assessed by using MitoSOX Red followed by cytofluorimetric analysis; (c) SOD2 levels were evaluated by performing Western blot analysis. Results are expressed as the . , , and . Graphs illustrate three different experiments conducted separately.

Oxidative stress and increase in ROS production are another typical feature of adipogenesis and obesity [28]. Based on this evidence, we measured ROS production in mature adipocytes following TR administration. In TR-treated cells, ROS levels were significantly reduced at both 300 and 500 μM (), compared to control cells (Figure 3(b)). In association with the decrease in oxidative stress, enhanced levels of the antioxidant enzyme, the Superoxide Dismutase 2 (SOD2), were observed in 500 μM TR-treated cells, suggesting, at least in part, a direct association with the observed blunt in ROS production () (Figure 3(c)). TR may contribute to improving the altered systemic condition caused by obesity through its anti-inflammatory and antioxidant role.

3.4. TR Irreversibly Inhibits Adipogenesis by Acting through Proliferation and Differentiation Processes

We investigated whether the inhibitory effect of TR on adipogenesis might be reversible by treating cells with TR (300 or 500 μM) from day 0 to day 2 (early stage of differentiation). Subsequently, TR was removed, and fresh differentiation medium was administered up to day 10. As shown in Figure 4(a), by Oil Red O staining, a slight but significant inhibition of cellular differentiation was observed after treatment with 500 μM TR (), compared to untreated cells, suggesting that TR irreversibly blunts cell adipogenesis by acting at the early stage of differentiation. Since we previously observed a reduction in preadipocyte viability after TR administration, we then evaluated whether TR acted on cell survival and proliferation during the mitotic clonal expansion (MCE). Thus, cell differentiation was induced, and TR was added from day 0 to day 2. The results show that TR at both doses, 300 and/or 500 μM, inhibited MCE, as reported by Trypan blue staining, compared to untreated cells () (Figure 4(b)). Inhibition of cell proliferation was also confirmed by measuring the whole cell cycle analysis. As reported in Figure 4(c), TR administration at both 300 and 500 μM induced cell cycle arrest in G1 phase compared to control cells (). To further validate these data, an increase in the steady-state levels of p21 (Figure 4(d)), a well-established inhibitor of cell cycle progression [29], and a reduction in cyclin D3 levels, a promoter of cell cycle progression (Figure 4(e)) [30], were evident in TR-treated cells, compared to control cells (). All these findings corroborated the role of TR in reducing adipogenesis by exerting its main action during specific steps of cellular proliferation and differentiation.

(a)

(b)

(c)

(d)

(e)

Figure 4

TR effect on MCE and irreversibility of adipogenesis impairment in 3T3-L1. Cells were seeded at a density of cells/well in a 24-well plate. (a) Differentiation was induced at day 0 with or without TR up to day 2, and then, fresh medium without TR was changed up to day 10. Oil Red O staining at day 10 was performed, and lipid content was quantified by measuring absorbance. (b) Cell proliferation was assessed by using the Trypan blue exclusion assay at day 0 and day 2 (representing the MCE). (c) Cell cycle analysis was performed by using Propidium Iodide followed by cytofluorimetric analysis. (d, e) Cell cycle arrest was evaluated by measuring steady-state levels of p21, and cyclin D3 by performing Western blot analysis. Results are expressed as the . and . Graphs illustrate three different experiments conducted separately.

3.5. TR Treatment Reduces Intracellular Lipid Storage by Triggering Adipose Tissue Browning

Given the established role of AMP-Activated Protein Kinase (AMPK) as an adipose tissue sensor of the intracellular energy state, and based on its antiadipogenic role [31, 32], to better understand the mechanistic process of TR-mediated antiadipogenic effect, we investigated the AMPK activation in this process. As reported in Figure 5(a), TR 500 μM determined a significant increase in AMPK-α phosphorylation at threonine-172 (Thr172), following 3T3-L1 cell differentiation compared to control cells ().

(a)

(b)

(c)

(d)

Once activated, AMPK phosphorylates Adipose Triglyceride Lipase (ATGL) at serine-406 (Ser406) leading to an increase of lipolysis in adipose tissue [33, 34]. We examined ATGL activation in 3T3-L1 adipocytes upon treatment with TR, and we observed an enhancement in the phosphorylation of ATGL at Ser406 after differentiation () (Figure 5(b)). We then analyzed the phosphorylation at Ser565 of hormone-sensitive lipase (HSL), another key factor of lipolysis regulated by AMPK [35]. According to AMPK activation, HSL phosphorylation increased following TR 500 μM administration () (Figure 5(c)). Intriguingly, the activatory phosphorylation of AMPK (Thr172) following TR treatment and the subsequent increase in ATGL-mediated lipolysis promote uncoupling protein 1 (UCP1) expression leading to the initial step of adipose tissue browning [36]. Accordingly, both TR 300 and 500 μM enhanced the expression levels of UCP1 in fully differentiated 3T3-L1 ( and , respectively) (Figure 5(d)), suggesting that TR administration may reduce adipogenesis by promoting adipose tissue browning.

4. Discussion

In the present study, we reported the beneficial effect of Tyrosol on reducing adipogenesis and proliferation of murine preadipocyte cell line 3T3-L1. In particular, TR administration significantly reduced adipogenesis by inhibiting the CEBP/α and regulating Sirt1/PPARγ pathways. Moreover, treatment with TR at specific doses determined a significant reduction in markers of inflammation and oxidative stress, which are typical processes related to complications of obesity, and may be also helpful during cardiometabolic rehabilitation following cardiometabolic alterations due to obesity. Hence, we reported that TR permanently reduced adipogenesis by blunting cell proliferation and differentiation, which may significantly lead to a decrease in fat mass accumulation and contribute to preventing adipose dysfunction in the context of obesity. Finally, we demonstrated that TR effect on adipogenesis is also directly mediated by activation of AMP kinase, which allows switching adipogenesis into adipose tissue browning, as per the UCP1 levels present after TR treatment.

Several studies reported that bioactive compounds, such as quercetin and epicatechin, by reducing preadipocyte viability (increasing cell death), may contribute to reducing adipose mass [37–39]. The action of these dietary stilbenes and flavonoids in preventing preadipocyte accumulation was more related to their abilities in counteracting the proaggregate function of oxidative stress. In the present study, we demonstrated that TR administration significantly decreases 3T3-L1 viability. Therefore, we may speculate that TR induces direct damage on preadipocytes that may contribute to reducing cell differentiation, adipogenesis, and total fat mass content. This hypothesis is further supported by the effect of Rhodiola crenulata, containing TR as a major bioactive phenolic compound, on the inhibition of the activities of proline dehydrogenase (PDH) and glucose-6-phosphate dehydrogenase (G6PDH) [17]. PDH and G6PDH activities are essentials for lipid metabolism related to the cellular structure and survival [40].

In line with our findings, besides inhibition of cell viability, previous studies reported that polyphenols may regulate adipose mass by blunting adipogenesis [10]. Association of resveratrol and quercetin significantly reduced lipid accumulation during 3T3-L1 differentiation [10] through a decrease in CEBP/α and PPARγ gene expression [10]. Similar evidence on the decline in CEBP/α and PPARγ gene expression was reported in association with impairment in 3T3-L1 differentiation following resveratrol administration [41]. Here, we also observed a reduction in total lipid accumulation on preadipocytes after TR administration, in association with a significant decrease in CEBP/α and PPARγ protein expression. PPARγ and CEBP/α are the main transcriptional factors for numerous genes during adipocyte differentiation [42]. Among those, Glut4 levels increase during adipogenesis [26]. We demonstrated an increase in Glut4 expression levels during 3T3-L1 differentiation, although a significant reduction of Glut4 levels was observed on day 10 in TR-treated cells. Glut4 is the transporter responsible for glucose uptake by adipocytes; therefore, its activity is pivotal for adipose tissue growth, while lower physiological levels of this transporter may result in prevention of obesity and diabetes [43]. It is worthy to note that downregulation of Glut4-related pathways is linked with increased risk for insulin resistance [44]. However, this association is mainly reported at the skeletal muscle level that accounts for ~80% of glucose uptake after food intake. Our results in adipocytes may not be detrimental since reduction of glucose uptake at adipose tissue levels may be counteracted at the muscle level. SREBP1c represents an important adipogenic regulator factor, directly controlled by CEBP/α [45], which increases adipogenesis by inducing PPARγ activation [46]. In our experimental model, SREBP1c levels are significantly decreased in the latest stage of differentiation, after TR administration. Similar findings were reported on preadipocytes following administration of HT and oleuropein, two relevant bioactive compounds present on EVOO [16]. In fact, HT has been indicated among the most powerful antioxidants in the context of metabolic syndrome (body weight/adiposity, dyslipidemia, hypertension, and hyperglycemia/insulin resistance) and associated complications (oxidative stress and inflammation) [47]. However, some differences exist between HT and TR, especially in terms of nutrient concentration, such as in EVOO, where TR is significantly more present [48]. The presence of TR has been also described in red wine and green tea besides EVOO [49]. However, to the best of our knowledge, no data are available so far on the direct role of TR in adipogenesis and related diseases, and the present study is the first in presenting these findings.

Recently, adipogenesis has been demonstrated to be regulated by Sirt1. Sirt1 belongs to the 7 sirtuins, a class III histone deacetylase regulating aging processes and metabolic homeostasis [50]. In particular, Sirt1 deletion or inactivation leads to an increase in adipose tissue and metabolic dysfunction [51]. It has been demonstrated that knockdown for Sirt1 in adipocytes determines an increase in PPARγ levels, which promotes adipogenesis [52], while Sirt1 overexpression in 3T3-L1 blunts adipogenesis by reducing PPARγ expression, and decreases fat accumulation in mature adipocytes [27]. These evidences suggest that the Sirt1 controls adipogenesis in a PPARγ-related way; however, a relevant role of CEBP/α in regulating Sirt1 expression during adipogenesis has also been reported yet [53]. Here, we showed that TR administration significantly increased Sirt1 expression, with a subsequent reduction in PPARγ, suggesting that TR antiadipogenic effect may be mediated, at least in part, by the Sirt1 pathway.

Since all the mechanisms previously described, especially Sirt1 and PPARγ-mediated pathways, are strongly associated with inflammation and oxidative stress in metabolic diseases [54], we evaluated markers of these processes in preadipocytes after TR treatment. The reduction of TNFα, which is a proinflammatory cytokine [55], is in line with other studies demonstrating the anti-inflammatory role of TR mediated at different levels, including COX-2 expression [56]. Similarly, reduction in ROS production and increase in SOD2 expression, an endogenous antioxidant defense that is significantly decreased in obesity [57], after TR treatment, are in line with the antioxidant activities of the enzymes present in EVOO [56]. These evidences suggest the hypothesis of its possible use as a therapeutic option against obesity, since inflammation and oxidative stress in mature adipocytes represent the main mechanisms leading to major complications, such as diabetes and cardiovascular events [58].

To investigate at which differentiation stage TR exerts its antiadipogenic effect, we tested the association between TR and mitotic clonal expansion (MCE), as a mandatory stage for successful adipogenesis [59]. TR administration during MCE significantly impaired adipogenesis by blunting adipocyte proliferation and by inducing cell cycle arrest, as further confirmed by both the increase in G1 phase and the steady-state level of p21. Based on these results, it is possible to state that TR acts on these cellular processes in a similar manner and magnitude of HT and oleuropein, as previously reported [16]. Other evidences on cocoa polyphenol extract and their role in suppressing adipogenesis during MCE, and in inducing cell cycle arrest during preadipocyte (3T3-L1) differentiation [60], further support the present findings. Treatment with TR significantly reduces cyclin D3 levels in our cellular models. Cyclin D3 promotes adipogenesis through the induction of PPARγ expression [61]. Consistently, it has been shown that cyclin D3 knockdown mice reduced intracellular lipid accumulation in association with decreased levels of PPARγ [61]. Therefore, taken together, our data suggest that TR reduces adipogenesis mainly throughout the inactivation of PPARγ-mediated pathways.

Finally, to go in deep in investigating the mechanistic processes beyond TR effect, we evaluated the modulation of several factors linked to lipolysis. These factors mainly require AMPK for its activation, which ultimately leads to fatty acid release. Furthermore, lipolysis requires also the activation of lipases, such as HSL and ATGL [33]. Upon treatment of adipocyte cultures with TR, we observed that TR induces AMPK activation in association with the increase in ATGL phosphorylation at Ser406, which enhances its hydrolase activity. Moreover, TR also stimulated HSL activation, suggesting that TR specifically affects ATGL function in the adipocyte. The activation of this pathway might explain the reduction in intracellular lipid droplet size, as well as the upregulation of brown adipocyte marker (UCP1) in cell cultures following TR administration, in a dose-dependent manner. In agreement, Ahmadian et al. suggested that ATGL hydrolase activity within adipocytes may lead to UCP1 expression promoting adipose tissue browning [62]. UCP1, in fact, represents the hallmark of brown adipose tissue (BAT) and is a reliable marker of browning of white adipose tissue (WAT), which has been shown to protect from obesity and type 2 diabetes [63]. In accordance with our results, it has been reported that a natural flavonoid protects from altered adipogenesis and obesity by inducing browning of WAT [63]. Thus, our data suggest that the proposed antiadipogenic effect of TR may be mediated by activation of the AMPK-ATGL-UCP1 pathway, leading to browning of WAT. However, further studies are needed to corroborate the present results.

Strengths of this study include the use of two different dosages of TR, tests performed in differentiated and not differentiated cells, and a follow-up time of 10 days that allowed catching differences between cellular groups. The main limitation to acknowledge is related to the impossibility of controlling and measuring all potential molecular pathways activated by TR to control adipogenesis. Moreover, it is important to highlight that this is a study only conducted in vitro in a single cellular line with high concentration of TR. Therefore, conclusions should be taken with caution and may not be conclusive since further in vivo studies with mice fed a high-fat diet are mandatory to prove the concept.

5. Conclusions

In the present study, we report a direct antiadipogenic effect of TR as the main EVOO bioactive compound. The TR beneficial role in adipogenesis is exerted by the inhibition of adipocyte differentiation and proliferation mainly through modulation of PPARγ-related pathways and then the inhibition of inflammation and oxidative stress and by switching WAT to BAT (Figure 6). Therefore, a diet with nutrients containing TR, especially after validation of the present data with in vivo studies conducted on mice fed a high-fat diet, may be proposed for its potential therapeutic application for the prevention of obesity and to improve quality of life.

Data Availability

All data are available to the readers by directly contacting the corresponding author in the email reported on the first page.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this article.

Acknowledgments

We thank Professor Paola Sinibaldi Salimei and the Master Degree in Physical Activity and Health Promotion, University of Rome Tor Vergata, 00133, Rome, Italy. This work has been supported by the following institutes and grants: Master Degree in Physical Activity and Health Promotion, School of Medicine, Università degli Studi di Roma Tor Vergata, Rome, Italy; Fondazione Umberto Di Mario; ASI N 2013-084-R0, COREA Research Project, Italian Space Agency; Evelyn F. McKnight Brain Research Foundation, Department of Neurology, University of Miami, Miami, FL, USA; PRIN 2017, #201793XZ5A_004, “Metabolic therapy of immuno-inflammation: in search for the best strategy to counteract type 2 diabetes and its complications”; Fondazione Roma—Diabetes Mellitus, Regenerative and Reparative Processes, and Improvement of Pancreatic Beta Cell Function: Role of Bone Marrow-Mesenchymal Stem Cells, MicroRNAs, M2 Macrophages and Myeloid Derived Suppressor Cells; and European Social Fund, under the Italian Ministry of Education, University and Research (MIUR) (PNR 2015-2020 ARS01_01163 PerMedNet—CUP B66G18000220005), and Italian Ministry of Health (Ricerca Corrente).

References

J. J. Reilly, A. el-Hamdouchi, A. Diouf, A. Monyeki, and S. A. Somda, “Determining the worldwide prevalence of obesity,” The Lancet, vol. 391, no. 10132, pp. 1773-1774, 2018.
View at: Publisher Site | Google Scholar
P. E. Scherer and J. A. Hill, “Obesity, diabetes, and cardiovascular diseases: a compendium,” Circulation Research, vol. 118, no. 11, pp. 1703–1705, 2016.
View at: Publisher Site | Google Scholar
S. B. Heymsfield and T. A. Wadden, “Mechanisms, pathophysiology, and management of obesity,” The New England Journal of Medicine, vol. 376, no. 3, pp. 254–266, 2017.
View at: Publisher Site | Google Scholar
M. Lafontan, “Fat cells: afferent and efferent messages define new approaches to treat obesity,” Annual Review of Pharmacology and Toxicology, vol. 45, no. 1, pp. 119–146, 2005.
View at: Publisher Site | Google Scholar
K. Smitka and D. Maresova, “Adipose tissue as an endocrine organ: an update on pro-inflammatory and anti-inflammatory microenvironment,” Prague Medical Report, vol. 116, no. 2, pp. 87–111, 2015.
View at: Publisher Site | Google Scholar
T. Pischon, S. E. Hankinson, G. S. Hotamisligil, N. Rifai, and E. B. Rimm, “Leisure-time physical activity and reduced plasma levels of obesity-related inflammatory markers,” Obesity Research, vol. 11, no. 9, pp. 1055–1064, 2003.
View at: Publisher Site | Google Scholar
J. D. Ard, B. Gower, G. Hunter et al., “Effects of calorie restriction in obese older adults: the CROSSROADS randomized controlled trial,” The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, vol. 73, no. 1, pp. 73–80, 2016.
View at: Publisher Site | Google Scholar
N. Siriwardhana, N. S. Kalupahana, M. Cekanova, M. LeMieux, B. Greer, and N. Moustaid-Moussa, “Modulation of adipose tissue inflammation by bioactive food compounds,” The Journal of Nutritional Biochemistry, vol. 24, no. 4, pp. 613–623, 2013.
View at: Publisher Site | Google Scholar
Y. Zhao, B. Chen, J. Shen et al., “The beneficial effects of quercetin, curcumin, and resveratrol in obesity,” Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 1459497, 8 pages, 2017.
View at: Publisher Site | Google Scholar
J. Y. Yang, M. A. Della-Fera, S. Rayalam et al., “Enhanced inhibition of adipogenesis and induction of apoptosis in 3T3-L1 adipocytes with combinations of resveratrol and quercetin,” Life Sciences, vol. 82, no. 19-20, pp. 1032–1039, 2008.
View at: Publisher Site | Google Scholar
S. Castro-Barquero, R. Lamuela-Raventós, M. Doménech, and R. Estruch, “Relationship between Mediterranean dietary polyphenol intake and obesity,” Nutrients, vol. 10, no. 10, p. 1523, 2018.
View at: Publisher Site | Google Scholar
V. Neveu, J. Perez-Jimenez, F. Vos et al., “Phenol-Explorer: an online comprehensive database on polyphenol contents in foods,” Database, vol. 2010, article bap024, 2010.
View at: Publisher Site | Google Scholar
S. Cicerale, L. Lucas, and R. Keast, “Biological activities of phenolic compounds present in virgin olive oil,” International Journal of Molecular Sciences, vol. 11, no. 2, pp. 458–479, 2010.
View at: Publisher Site | Google Scholar
C. Pérez-Mañá, M. Farré, J. Rodríguez-Morató et al., “Moderate consumption of wine, through both its phenolic compounds and alcohol content, promotes hydroxytyrosol endogenous generation in humans. A randomized controlled trial,” Molecular Nutrition & Food Research, vol. 59, no. 6, pp. 1213–1216, 2015.
View at: Publisher Site | Google Scholar
M. N. Vissers, P. L. Zock, A. J. C. Roodenburg, R. Leenen, and M. B. Katan, “Olive oil phenols are absorbed in humans,” The Journal of Nutrition, vol. 132, no. 3, pp. 409–417, 2002.
View at: Publisher Site | Google Scholar
R. Drira, S. Chen, and K. Sakamoto, “Oleuropein and hydroxytyrosol inhibit adipocyte differentiation in 3 T3-L1 cells,” Life Sciences, vol. 89, no. 19-20, pp. 708–716, 2011.
View at: Publisher Site | Google Scholar
O. H. Lee, Y. I. Kwon, E. Apostolidis, K. Shetty, and Y. C. Kim, “Rhodiola-induced inhibition of adipogenesis involves antioxidant enzyme response associated with pentose phosphate pathway,” Phytotherapy Research, vol. 25, no. 1, pp. 106–115, 2011.
View at: Publisher Site | Google Scholar
K. Zebisch, V. Voigt, M. Wabitsch, and M. Brandsch, “Protocol for effective differentiation of 3T3-L1 cells to adipocytes,” Analytical Biochemistry, vol. 425, no. 1, pp. 88–90, 2012.
View at: Publisher Site | Google Scholar
V. Rizzatti, F. Boschi, M. Pedrotti, E. Zoico, A. Sbarbati, and M. Zamboni, “Lipid droplets characterization in adipocyte differentiated 3T3-L1 cells: size and optical density distribution,” European Journal of Histochemistry, vol. 57, no. 3, article e24, 2013.
View at: Publisher Site | Google Scholar
C. Roh, U. Jung, and S. K. Jo, “Screening of anti-obesity agent from herbal mixtures,” Molecules, vol. 17, no. 4, pp. 3630–3638, 2012.
View at: Publisher Site | Google Scholar
F. Pacifici, R. Arriga, G. P. Sorice et al., “Peroxiredoxin 6, a novel player in the pathogenesis of diabetes,” Diabetes, vol. 63, no. 10, pp. 3210–3220, 2014.
View at: Publisher Site | Google Scholar
L. Palhinha, S. Liechocki, E. D. Hottz et al., “Leptin induces proadipogenic and proinflammatory signaling in adipocytes,” Frontiers in Endocrinology, vol. 10, p. 841, 2019.
View at: Publisher Site | Google Scholar
M. E. Ertunc, J. Sikkeland, F. Fenaroli et al., “Secretion of fatty acid binding protein aP2 from adipocytes through a nonclassical pathway in response to adipocyte lipase activity,” Journal of Lipid Research, vol. 56, no. 2, pp. 423–434, 2015.
View at: Publisher Site | Google Scholar
E. D. Rosen, C. H. Hsu, X. Wang et al., “C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway,” Genes & Development, vol. 16, no. 1, pp. 22–26, 2002.
View at: Publisher Site | Google Scholar
K. Choi, B. Ghaddar, C. Moya et al., “Analysis of transcription factor network underlying 3T3-L1 adipocyte differentiation,” PLoS One, vol. 9, no. 7, article e100177, 2014.
View at: Publisher Site | Google Scholar
R. M. Jackson, B. A. Griesel, J. M. Gurley, L. I. Szweda, and A. L. Olson, “Glucose availability controls adipogenesis in mouse 3T3-L1 adipocytes via up-regulation of nicotinamide metabolism,” The Journal of Biological Chemistry, vol. 292, no. 45, pp. 18556–18564, 2017.
View at: Publisher Site | Google Scholar
F. Picard, M. Kurtev, N. Chung et al., “Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma,” Nature, vol. 429, no. 6993, pp. 771–776, 2004.
View at: Publisher Site | Google Scholar
Y. Okuno, A. Fukuhara, E. Hashimoto et al., “Oxidative stress inhibits healthy adipose expansion through suppression of SREBF1-mediated lipogenic pathway,” Diabetes, vol. 67, no. 6, pp. 1113–1127, 2018.
View at: Publisher Site | Google Scholar
A. Karimian, Y. Ahmadi, and B. Yousefi, “Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage,” DNA Repair, vol. 42, pp. 63–71, 2016.
View at: Publisher Site | Google Scholar
Y. Fan, C. K. P. Mok, M. C. W. Chan et al., “Cell cycle-independent role of cyclin D3 in host restriction of influenza virus infection,” The Journal of Biological Chemistry, vol. 292, no. 12, pp. 5070–5088, 2017.
View at: Publisher Site | Google Scholar
B. Ahmad, C. J. Serpell, I. L. Fong, and E. H. Wong, “Molecular mechanisms of adipogenesis: the anti-adipogenic role of AMP-activated protein kinase,” Frontiers in Molecular Biosciences, vol. 7, p. 76, 2020.
View at: Publisher Site | Google Scholar
M. Daval, F. Foufelle, and P. Ferre, “Functions of AMP-activated protein kinase in adipose tissue,” The Journal of Physiology, vol. 574, no. 1, pp. 55–62, 2006.
View at: Publisher Site | Google Scholar
R. E. Duncan, M. Ahmadian, K. Jaworski, E. Sarkadi-Nagy, and H. S. Sul, “Regulation of lipolysis in adipocytes,” Annual Review of Nutrition, vol. 27, no. 1, pp. 79–101, 2007.
View at: Publisher Site | Google Scholar
V. Marzolla, A. Feraco, S. Gorini et al., “The novel non-steroidal MR antagonist finerenone improves metabolic parameters in high-fat diet-fed mice and activates brown adipose tissue via AMPK-ATGL pathway,” The FASEB Journal, vol. 34, no. 9, pp. 12450–12465, 2020.
View at: Publisher Site | Google Scholar
W. J. Shen, Z. Yu, S. Patel, D. Jue, L. F. Liu, and F. B. Kraemer, “Hormone-sensitive lipase modulates adipose metabolism through PPARγ,” Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, vol. 1811, no. 1, pp. 9–16, 2011.
View at: Publisher Site | Google Scholar
A. Kuryłowicz and M. Puzianowska-Kuźnicka, “Induction of adipose tissue browning as a strategy to combat obesity,” International Journal of Molecular Sciences, vol. 21, no. 17, p. 6241, 2020.
View at: Publisher Site | Google Scholar
D. G. Popovich, L. Li, and W. Zhang, “Bitter melon (Momordica charantia) triterpenoid extract reduces preadipocyte viability, lipid accumulation and adiponectin expression in 3T3-L1 cells,” Food and Chemical Toxicology, vol. 48, no. 6, pp. 1619–1626, 2010.
View at: Publisher Site | Google Scholar
S. Hatia, A. Septembre-Malaterre, F. le Sage et al., “Evaluation of antioxidant properties of major dietary polyphenols and their protective effect on 3T3-L1 preadipocytes and red blood cells exposed to oxidative stress,” Free Radical Research, vol. 48, no. 4, pp. 387–401, 2014.
View at: Publisher Site | Google Scholar
J. T. Hwang, M. S. Lee, H. J. Kim et al., “Antiobesity effect of ginsenoside Rg3 involves the AMPK and PPAR-gamma signal pathways,” Phytotherapy Research, vol. 23, no. 2, pp. 262–266, 2009.
View at: Publisher Site | Google Scholar
R. C. Stanton, “Glucose-6-phosphate dehydrogenase, NADPH, and cell survival,” IUBMB Life, vol. 64, no. 5, pp. 362–369, 2012.
View at: Publisher Site | Google Scholar
S. Chen, Z. Li, W. Li, Z. Shan, and W. Zhu, “Resveratrol inhibits cell differentiation in 3T3-L1 adipocytes via activation of AMPK,” Canadian Journal of Physiology and Pharmacology, vol. 89, no. 11, pp. 793–799, 2011.
View at: Publisher Site | Google Scholar
F. M. Gregoire, C. M. Smas, and H. S. Sul, “Understanding adipocyte differentiation,” Physiological Reviews, vol. 78, no. 3, pp. 783–809, 1998.
View at: Publisher Site | Google Scholar
R. Govers, “Molecular mechanisms of GLUT4 regulation in adipocytes,” Diabetes & Metabolism, vol. 40, no. 6, pp. 400–410, 2014.
View at: Publisher Site | Google Scholar
P. T. Xu, Z. Song, W. C. Zhang, B. Jiao, and Z. B. Yu, “Impaired translocation of GLUT4 results in insulin resistance of atrophic soleus muscle,” BioMed Research International, vol. 2015, Article ID 291987, 11 pages, 2015.
View at: Publisher Site | Google Scholar
V. A. Payne, W. S. Au, C. E. Lowe et al., “C/EBP transcription factors regulate SREBP1c gene expression during adipogenesis,” The Biochemical Journal, vol. 425, no. 1, pp. 215–223, 2009.
View at: Publisher Site | Google Scholar
L. Fajas, K. Schoonjans, L. Gelman et al., “Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism,” Molecular and Cellular Biology, vol. 19, no. 8, pp. 5495–5503, 1999.
View at: Publisher Site | Google Scholar
J. Peyrol, C. Riva, and M. J. Amiot, “Hydroxytyrosol in the prevention of the metabolic syndrome and related disorders,” Nutrients, vol. 9, no. 3, p. 306, 2017.
View at: Publisher Site | Google Scholar
C. Romero and M. Brenes, “Analysis of total contents of hydroxytyrosol and tyrosol in olive oils,” Journal of Agricultural and Food Chemistry, vol. 60, no. 36, pp. 9017–9022, 2012.
View at: Publisher Site | Google Scholar
A. A. Bertelli, “Wine, research and cardiovascular disease: instructions for use,” Atherosclerosis, vol. 195, no. 2, pp. 242–247, 2007.
View at: Publisher Site | Google Scholar
M. C. Haigis and D. A. Sinclair, “Mammalian sirtuins: biological insights and disease relevance,” Annual Review of Pathology, vol. 5, no. 1, pp. 253–295, 2010.
View at: Publisher Site | Google Scholar
A. Chalkiadaki and L. Guarente, “High-fat diet triggers inflammation-induced cleavage of SIRT1 in adipose tissue to promote metabolic dysfunction,” Cell Metabolism, vol. 16, no. 2, pp. 180–188, 2012.
View at: Publisher Site | Google Scholar
Y. Zhou, T. Song, J. Peng et al., “SIRT1 suppresses adipogenesis by activating Wnt/β-catenin signaling in vivo and in vitro,” Oncotarget, vol. 7, no. 47, pp. 77707–77720, 2016.
View at: Publisher Site | Google Scholar
Q. Jin, F. Zhang, T. Yan et al., “C/EBPα regulates SIRT1 expression during adipogenesis,” Cell Research, vol. 20, no. 4, pp. 470–479, 2010.
View at: Publisher Site | Google Scholar
F. Pacifici, D. di Cola, D. Pastore et al., “Proposed tandem effect of physical activity and sirtuin 1 and 3 activation in regulating glucose homeostasis,” International Journal of Molecular Sciences, vol. 20, article 4748, no. 19, 2019.
View at: Publisher Site | Google Scholar
S. Kany, J. T. Vollrath, and B. Relja, “Cytokines in inflammatory disease,” International Journal of Molecular Sciences, vol. 20, article 6008, no. 23, 2019.
View at: Publisher Site | Google Scholar
G. Serreli and M. Deiana, “Extra virgin olive oil polyphenols: modulation of cellular pathways related to oxidant species and inflammation in aging,” Cell, vol. 9, no. 2, p. 478, 2020.
View at: Publisher Site | Google Scholar
A. Fernández-Sánchez, E. Madrigal-Santillán, M. Bautista et al., “Inflammation, oxidative stress, and obesity,” International Journal of Molecular Sciences, vol. 12, no. 5, pp. 3117–3132, 2011.
View at: Publisher Site | Google Scholar
P. Manna and S. K. Jain, “Obesity, oxidative stress, adipose tissue dysfunction, and the associated health risks: causes and therapeutic strategies,” Metabolic Syndrome and Related Disorders, vol. 13, no. 10, pp. 423–444, 2015.
View at: Publisher Site | Google Scholar
Q. Q. Tang, T. C. Otto, and M. D. Lane, “Mitotic clonal expansion: a synchronous process required for adipogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 1, pp. 44–49, 2003.
View at: Publisher Site | Google Scholar
S. Y. Min, H. Yang, S. G. Seo et al., “Cocoa polyphenols suppress adipogenesis in vitro and obesity in vivo by targeting insulin receptor,” International Journal of Obesity, vol. 37, no. 4, pp. 584–592, 2013.
View at: Publisher Site | Google Scholar
D. A. Sarruf, I. Iankova, A. Abella, S. Assou, S.́. Miard, and L. Fajas, “Cyclin D3 promotes adipogenesis through activation of peroxisome proliferator-activated receptor gamma,” Molecular and Cellular Biology, vol. 25, no. 22, pp. 9985–9995, 2005.
View at: Publisher Site | Google Scholar
M. Ahmadian, M. J. Abbott, T. Tang et al., “Desnutrin/ATGL is regulated by AMPK and is required for a brown adipose phenotype,” Cell Metabolism, vol. 13, no. 6, pp. 739–748, 2011.
View at: Publisher Site | Google Scholar
Y. Han, J. Z. Wu, J. Z. Shen et al., “Pentamethylquercetin induces adipose browning and exerts beneficial effects in 3T3-L1 adipocytes and high-fat diet-fed mice,” Scientific Reports, vol. 7, no. 1, p. 1123, 2017.
View at: Publisher Site | Google Scholar

Copyright

Copyright © 2020 Francesca Pacifici et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

1267

Downloads

956

Citations